Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To study the medical cost and probability of relapse in patients with multiple sclerosis (MS) treated with either glatiramer acetate (GA) or interferon beta-1b (IFN beta.1b).
Data were obtained from the i3 InVision Data Mart™ Database from July 2001 to June 2006. We established an “intent-totreat” (ITT) cohort (n=842) of patients diagnosed with MS who began treatment with either GA or IFN beta-1b and had continuous insurance coverage from 6 months before to 2 years after the date when they began taking the medication. We also created a “continuous use” (CU) cohort (n=418) of individuals who, in addition to the criteria listed above, used either GA or IFN beta-1b within 28 days of the end of the 2-year postperiod. Using multivariate regressions, we examined both the 2-year total average direct medical costs and the likelihood of relapse within this period associated with the use of each of these MS medications. We defined relapse as being either hospitalization with a principal diagnosis of MS or having an outpatient visit with a diagnosis of MS and then prescribed steroids within a 7-day period. All regression analyses controlled for a wide range of factors that may potentially affect outcomes.
In the ITT cohort, patients who started treatment with GA had a significantly lower 2-year estimated risk of relapse (13.54% vs. 5.31%; P=0.0006). In the CU cohort, patients who used GA also had a significantly lower 2-year estimated risk of relapse (10.91% vs. 2.09%; P=0.0018), as well as significantly lower average total medical costs ($53,157 vs. $48,130; P=0.0345).
Results from this study indicate that users of GA have a significantly lower probability of 2-year relapse than users of IFN beta-1b. In addition, among continuous users, the 2-year total average direct medical costs are significantly lower for users of GA than for users of IFN beta-1b.
- Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4:111–121. CrossRef
- Frohman EM. Multiple sclerosis. Med Clin North Am. 2003;87:867–897, viii–ix. CrossRef
- Multiple Sclerosis International Federation. About MS: what is MS? http://www.msif.org/en/about_ms/what_is_ms.html. Accessed October 6, 2008.
- National Multiple Sclerosis Society. About MS: who gets MS? Available at http://www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/index.aspx. Accessed October 6, 2008.
- Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology. 2002;58:136–138.
- Richards RG, Sampson FC, Beard SM, Tappendon P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess. 2002;6:1–73.
- Multiple Sclerosis International Federation. About MS: introduction. http://www.msif.org/en/about_ms/index.html. Accessed October 6, 2008.
- Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry. 2000;68:144–149. CrossRef
- Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry. 1998;65:460–466. CrossRef
- Multiple Sclerosis International Federation. About MS: recognised treatment for MS. http://www.msif.org/en/about_ms/recognised_treat.html. Accessed October 6, 2008.
- Tullman MJ, Lublin FD, Miller AE. Immunotherapy of multiple sclerosis-current practice and future directions. J Rehab Res Dev. 2002;39:273–286.
- Calabresi P. Investigating glatiramer acetate for relapsing-remitting multiple sclerosis at the double dose-is more better? Nat Clin Pract Neurol. 2007;3:540–541. CrossRef
- Pohlman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. BMJ. 2000;321:490–494. CrossRef
- Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifroni G, Wolinsky JS. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler. 2006;12:309–320. CrossRef
- Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50:701–708.
- Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45:1268–1276.
- Khan OA, Tselis AC, Kamholz JA, et al. A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler. 2001;1:349–353.
- Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxoner). Eur J Neurol. 2005;12:4259–4431.
- Carra A, Onaha P, Sinay V, et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol. 2003;10:671–676. CrossRef
- Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother. 2001;2:1149–1165. CrossRef
- Davis WM. Multiple sclerosis: continuing mysteriesand current management. Drug Topics. 2000;144:93–102.
- Vallittu AM, Peltoniemi J, Elovaara I, et al. The efficacy of glatiramer acetate in beta-interferonintolerant MS patients. Acta Neurol Scand. 2005;112:234–237. CrossRef
- Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7:554–568. CrossRef
- Chilcott J, McCabe C, Tappenden P, et al. Modeling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326:522–525. CrossRef
- Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13:44–52.
- Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of 4 immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Phar. 2007;13:245–261.
- Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. Curr Opin CNS Drugs. 2004;18:561–574. CrossRef
- Bureau of Labor Statistics. Consumer Price Index. Available at http://www.bls.gov/cpi. Accessed April 20, 2009.
- Ollendorf D, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8:469–476.
- Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71:129–135. CrossRef
- National Multiple Sclerosis Society. About MS: epidemiology of MS. Available at http://www.nationalmssociety.org/about-multiple-sclerosis/whogets-ms/epidemiology-of-ms/index.aspx. Accessed October 8, 2008.
- Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008;14:1091–1098. CrossRef
- Miller A. Paroxysmal disorders. In: Burks JS, Johnson KP, eds. Multiple sclerosis: diagnosis, medical management, and rehabilitation. New York: Demos Medical Publishing, Inc.; 2000.
- Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs. 2008;22:291–324. CrossRef
- Trouillas P, Courjon J. Epilepsy with multiple sclerosis. Epilepsia. 2007;13:325–333. CrossRef
- Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler. 2000;6:255–266.
- IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277–1285.
- Kobelt G, Berg J, Atherley D, Hadjimichael O, Jonsson B. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. Neurology. 2006;66:1696–1702. CrossRef
- Whetten-Goldenstein K, Sloan FA, Goldenstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4:419–425.
- i3. Data assets: better data matters. http://www.i3-global.com/DataAssets. Accessed October 8, 2008.
- Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis
Advances in Therapy
Volume 26, Issue 5 , pp 552-562
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare Communications
- Additional Links
- glatiramer acetate
- interferon beta-1b
- medical costs
- multivariate analyses
- retrospective study
- Industry Sectors
- Author Affiliations
- 1. Teva Neuroscience, Kansas City, MO, 64131, USA
- 2. HealthMetrics Outcomes Research, Groton, CT, 06340, USA
- 3. University of Maryland and Maryland Center for Multiple Sclerosis, Baltimore, MD, USA